Heart rate-lowering drug improves exercise capacity in patients with stable angina

October 29, 2008

Results from a late-breaking clinical trial, presented at the 2008 Canadian Cardiology Congress (CCC) in Toronto, show for the first time that combining the pure heart rate reduction medication ivabradine to current treatments of patients with stable angina improves their exercise capacity.

The study involved almost 900 patients from Canada and internationally with documented coronary artery disease and a history of stable angina. The objective was to determine if treatment with ivabradine could improve exercise capacity in these patients beyond what was previously achieved with standard treatments. Patients received either ivabradine 5 mg bid for two months (increased to 7.5 mg bid in 87.5 percent of patients for an additional two months) or placebo for four months in addition to their current beta blocker background therapy (atenolol 50 mg daily).

"Our findings confirm that adding ivabradine over and above the standard of care achieves increases exercise tolerance," said Dr. Jean-Claude Tardif, the study's lead investigator, a professor of medicine at the Université de Montréal and director of the Montreal Heart Institute Research Centre.

"For patients who have stable angina the results are very encouraging, particularly because of tolerability concerns with higher doses of beta blockers. As a result patients are often not achieving optimal heart rate reduction on standard therapy alone," adds Dr. Tardif.

An analysis of the data from treadmill exercise tests shows that patients who were treated with ivabradine in addition to a beta blocker (n=441) demonstrated a threefold improvement in total exercise duration at four months compared to those being treated with standard doses of beta blocker alone.

After four months of treatment, the ivabradine and beta blocker combination was associated with a mean heart rate reduction of nine beats per minute (bpm) compared to one bpm in patients remaining on beta blockers alone. Patients receiving the ivabradine and beta blocker combination also had considerable improvements in symptoms and ischemia as measured by time to limiting angina, time to angina onset, and time to 1-mm ST-segment depression.

Ivabradine is not yet available for clinical use in Canada.
About Coronary Artery Disease

Coronary artery disease (CAD) is the most common manifestation of cardiovascular disease. It refers to the hardening and shrinking of the coronary arteries (atherosclerosis) which leads to diminished blood flow and reduces oxygen supply to the heart muscle (ischemia). The lack of oxygen supply to the heart muscle may cause angina (heart pain). If the coronary artery becomes completely blocked, a whole section of the heart muscle is deprived of oxygen and dies, resulting in a myocardial infarction (MI) or heart attack. Coronary artery disease is a progressive silent disease that very often is unobserved until the first symptoms of ischemia or MI occur. Although the prognosis of patients with CAD has been greatly improved by advances in cardiovascular treatment, it is still the first cause of death.

Cardiovascular disease accounts for the death of more Canadians than any other disease. In fact, in Canada someone dies every seven minutes from it. According to the latest statistics available from Statistics Canada, in 2004 cardiovascular disease accounted for close to one third of all deaths in Canada (more than 72,000 deaths).

Heart rate and CAD

Heart rate is a major determinant of oxygen consumption and can precipitate most episodes of ischemia, both symptomatic and silent. Consequently, lowering the heart rate in patients with CAD reduces the heart's need for oxygen. A number of epidemiological studies have shown that heart rate is a strong and independent predictor of cardiovascular events in a wide range of patients, including those with CAD and post-myocardial infarction. This risk seems to become particularly evident with heart rate above 70 bpm.

On the Web:

About the Montreal Heart Institute: www.icm-mhi.org.
About the Université de Montréal: www.umontreal.ca/english/index.htm.
About the Canadian Cardiovascular Congress: http://www.cardiocongress.org/english/index.html.

For further information, please contact:

Doris Prince
Head, Communication and Public Relations
Montreal Heart Institute
Telephone: 514 376-3330, poste 3074
Email: doris.prince@icm-mhi.org

University of Montreal

Related Beta Blockers Articles from Brightsurf:

L-type calcium channel blockers may contribute to heart failure, study finds
Researchers found that in rats and human cells in vitro, LCCBs cause changes in blood vessels -- known as vascular remodeling -- that reduce blood flow and increase pressure.

Women taking beta blockers for hypertension may have higher risk of heart failure with acute coronary syndrome
Women have historically been underrepresented in past clinical research, raising concerns about their use of beta blockers as a treatment for hypertension.

Ad blockers may benefit websites, users, and the market at large
A new study sought to determine the effect of ad blockers on websites' ability to generate revenue and on users' experiences.

ACE inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19
James Diaz, MD, MHA, MPH & TM, Dr PH, Professor and Head of Environmental Health Sciences at LSU Health New Orleans School of Public Health, has proposed a possible explanation for the severe lung complications being seen in some people diagnosed with COVID-19.

Why beta-blockers cause skin inflammation
Beta-blockers are often used to treat high blood pressure and other cardiovascular diseases.

Calcium channel blockers may be effective in treating memory loss in Alzheimer's disease
Alzheimer's disease (AD) is the most common cause of dementia but the changes in brain cell function underlying memory loss remains poorly understood.

Beta blockers reduce stress-induced irregular heart rhythm
Taking beta blockers -- medications that reduce blood pressure and treat many heart conditions -- can blunt the negative effects of stress and anger on people with a history of atrial fibrillation, or irregular heart rhythm, said Yale researchers.

Beta blockers can block the effects of stress and anger in patients prone to emotion-triggered atrial fibrillation
Individuals who are prone to emotion-triggered atrial fibrillation (AF) may benefit from taking beta blockers.

Tumor-selective angiotensin blockers may improve response to cancer immunotherapy
A research team led by investigators at Massachusetts General Hospital and the Massachusetts Institute of Technology has found that combining a specialized version of an antihypertension drug with immune checkpoint blockers could increase the effectiveness of cancer immunotherapies.

Angiotensin receptor blockers normalize sodium excretion
Drugs that inhibit a hormone that constricts blood vessels also help improve sodium excretion in blacks who hold onto too much sodium in the face of stress, investigators report.

Read More: Beta Blockers News and Beta Blockers Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.